2015
DOI: 10.1161/atvbaha.115.306558
|View full text |Cite
|
Sign up to set email alerts
|

Neovascularization Driven by MicroRNA Delivery to the Endothelium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 21 publications
(24 reference statements)
0
3
0
Order By: Relevance
“…Delivery of miR-126 to the ECs of vessels in ischemic rat hind limb with this method resulted in downregulation of known miR-126 target genes only in ECs and not in liver and spleen as common off-target organs, and increased vessel length, vascular density, and tissue perfusion [160] . UTMD is shown to be an efficient cell-specific method of miRNA delivery and less invasive in comparison to other delivery methods [13] . Although the study was performed in the model of hind limb ischemia, it is likely that it can also be applied to study the effect of miRNA delivery to cardiac ECs in the context of pathological remodeling.…”
Section: Angiogenic Ncrnas As Potential Therapeutic Targets For Heartmentioning
confidence: 99%
See 2 more Smart Citations
“…Delivery of miR-126 to the ECs of vessels in ischemic rat hind limb with this method resulted in downregulation of known miR-126 target genes only in ECs and not in liver and spleen as common off-target organs, and increased vessel length, vascular density, and tissue perfusion [160] . UTMD is shown to be an efficient cell-specific method of miRNA delivery and less invasive in comparison to other delivery methods [13] . Although the study was performed in the model of hind limb ischemia, it is likely that it can also be applied to study the effect of miRNA delivery to cardiac ECs in the context of pathological remodeling.…”
Section: Angiogenic Ncrnas As Potential Therapeutic Targets For Heartmentioning
confidence: 99%
“…Despite the conflicting results from past and ongoing clinical trials, pre-clinical in vivo studies show clear improved cardiac function after neovascularization by enhancing capillary density with pro-angiogenic compounds [9] , [10] , [11] . One of the possible reasons for this discrepancy is the common use of single pro-angiogenic agents, mostly considered insufficient to boost angiogenesis in the heart [12] , [13] .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation